| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA2G7 |
| Uniprot No | Q13093 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-441aa |
| 氨基酸序列 | FDWQYINPV AHMKSSAWVN KIQVLMAAAS FGQTKIPRGN GPYSVGCTDL MFDHTNKGTF LRLYYPSQDN DRLDTLWIPN KEYFWGLSKF LGTHWLMGNI LRLLFGSMTT PANWNSPLRP GEKYPLVVFS HGLGAFRTLY SAIGIDLASH GFIVAAVEHR DRSASATYYF KDQSAAEIGD KSWLYLRTLK QEEETHIRNE QVRQRAKECS QALSLILDID HGKPVKNALD LKFDMEQLKD SIDREKIAVI GHSFGGATVI QTLSEDQRFR CGIALDAWMF PLGDEVYSRI PQPLFFINSE YFQYPANIIK MKKCYSPDKE RKMITIRGSV HQNFADFTFA TGKIIGHMLK LKGDIDSNVA IDLSNKASLA FLQKHLGLHK DFDQWDCLIE GDDENLIPGT NINTTNQHIM LQNSSGIEKY N |
| 预测分子量 | 49 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Expression, purification, and characterization of recombinant human platelet-activating factor acetylhydrolase"** by Stafforini DM et al.
- 摘要：该研究描述在大肠杆菌中重组表达人PLA2G7(PAF-AH)，通过亲和层析纯化获得高活性酶，并验证其降解PAF(血小板活化因子)的能力，为研究其抗炎机制提供工具。
2. **"Darapladib for preventing ischemic events in stable coronary heart disease"** by Serruys PW et al.
- 摘要：临床试验评估PLA2G7抑制剂Darapladib对冠心病患者的作用，发现其抑制重组PLA2G7活性可降低动脉粥样硬化斑块炎症标志物，但对主要心血管事件影响有限。
3. **"Lipoprotein-associated phospholipase A2: A potential therapeutic target for atherosclerosis"** by Wilensky RL et al.
- 摘要：通过动物模型证明，重组PLA2G7的抑制可减少动脉粥样硬化病变进展，强调其氧化磷脂水解活性在炎症通路中的关键作用及治疗潜力。
4. **"Structural determinants of lipoprotein-associated phospholipase A2 activity and specificity"** by Tselepis AD et al.
- 摘要：利用重组PLA2G7蛋白进行结构-功能分析，揭示其底物结合域的关键氨基酸残基，阐明其对氧化磷脂底物的特异性识别机制。
PLA2G7. also known as lipoprotein-associated phospholipase A2 (Lp-PLA2) or platelet-activating factor acetylhydrolase (PAF-AH), is a calcium-independent phospholipase enzyme encoded by the PLA2G7 gene. It is primarily secreted by macrophages, lymphocytes, and hepatocytes, circulating in plasma bound to low-density lipoproteins (LDL) and high-density lipoproteins (HDL). This 45-kDa enzyme hydrolyzes oxidized phospholipids in oxidized LDL, generating pro-inflammatory mediators (lysophosphatidylcholine and oxidized fatty acids) that contribute to vascular inflammation and atherosclerosis. Its dual role in lipid metabolism and inflammation has made it a biomarker for cardiovascular disease risk assessment.
Recombinant PLA2G7 protein is produced using expression systems such as mammalian cells (e.g., HEK293) or Escherichia coli, ensuring proper post-translational modifications for enzymatic activity. The purified protein retains the ability to catalyze the hydrolysis of PAF and oxidized phospholipids, making it valuable for functional studies, inhibitor screening, and diagnostic assay development. Researchers utilize it to investigate mechanisms linking lipid oxidation to atherosclerosis, neuroinflammation (e.g., Alzheimer's disease), and autoimmune disorders.
Pharmaceutical interest in PLA2G7 stems from its therapeutic potential. While early clinical trials with Lp-PLA2 inhibitors like darapladib showed mixed cardiovascular outcomes, recombinant PLA2G7 remains crucial for structure-function studies and targeted drug design. Additionally, its quantification in clinical samples aids in evaluating cardiovascular risk stratification strategies. Current applications extend to developing neutralizing antibodies and exploring its role in sepsis, where PAF degradation modulates inflammatory responses.
×
